Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

Accelerate medical breakthroughs by ending disease earmarks

Nature Reviews Genetics volume 11, pages 310–311 (2010)Cite this article

Subjects

Identifying connections among genetic diseases can accelerate the development of new therapies. If this potential is to be realized, argues Sharon F. Terry, research funding must no longer be focused on individual diseases.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Whalen, J. FDA approves a novel Novartis drug. Wall Street Journal B1 (19 Jun 2009).

  2. Collins, F. S. Unprecedented therapeutic opportunities for rare and neglected diseases. 2009 Genetic Alliance Annual Conference [online], (2009).

    Google Scholar 

  3. Lachmann, H. J. et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N. Engl. J. Med. 360, 2416–2425 (2009).

    Article  CAS  Google Scholar 

  4. McDermott, M. F. Rilonacept in the treatment of chronic inflammatory disorders. Drugs Today 45, 423–430 (2009).

    Article  CAS  Google Scholar 

  5. Matt, P. et al. Recent advances in understanding Marfan syndrome: should we now treat surgical patients with losartan? J. Thorac. Cardiovasc. Surg. 135, 389–394 (2008).

    Article  Google Scholar 

  6. [No authors listed.] Is inflammation the root of all disease? UC Berkeley Wellness Letter [online], (2008).

  7. Balkwill, F. & Mantovani A. Inflammation and cancer: back to Virchow? Lancet 357, 539–545 (2001).

    Article  CAS  Google Scholar 

  8. Leaf, C. Why we are losing the war on cancer: and how we can win it. Fortune 77–92 (9 Mar 2004).

Download references

Acknowledgements

The author thanks the many disease advocacy organizations for their hard work, and acknowledges the bold policy makers who put health above politics.

Author information

Authors and Affiliations

  1. Sharon F. Terry is at Genetic Alliance and PXE International, 4301 Connecticut Avenue, NW, Suite 404, Washington, DC 20008-2304, USA. sterry@geneticalliance.org; sterry@pxe.org,

    Sharon F. Terry

  2. sterry@pxe.org,

    Sharon F. Terry

Authors
  1. Sharon F. Terry
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Terry, S. Accelerate medical breakthroughs by ending disease earmarks. Nat Rev Genet 11, 310–311 (2010). https://doi.org/10.1038/nrg2782

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrg2782

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing